Interview with the CEO, President and Director: Aldeyra Therapeutics Inc. (NASDAQ:ALDX)

Healthcare >> CEO Interviews >> February 12, 2016

Todd C. Brady is CEO, President and Director of Aldeyra Therapeutics, Inc., and has more than 20 years of pharmaceutical clinical and business development experience. Prior to joining Aldeyra Therapeutics, Inc., in 2012, Dr. Brady was an entrepreneur-in-residence and principal at Domain Associates, where he led institutional financing in numerous biotechnology companies from 2004 to 2013. Prior to joining Domain, Dr. Brady was a Co-Founder and CEO of Phenome Sciences, a biotechnology firm he merged with Xanthus Pharmaceuticals — acquired by Antisoma — where he was later Executive Vice President of Strategic Development and Planning. Dr. Brady also worked as Head of Business Development and Medical Director at Aderis Pharmaceuticals — acquired by Schwarz Pharma, now part of UCB. While at Xanthus and Aderis, he was a medical consultant on numerous preclinical programs and clinical programs in Phases I through IV, including Neupro, a drug now marketed for Parkinson’s disease. Dr. Brady holds an M.D. from Duke University Medical School, a Ph.D. from Duke University Graduate School and an A.B. from Dartmouth College. Profile

TWST: If you would, please start with a bit of historical background on Aldeyra prior to its IPO?

Dr. Brady: We were a venture-backed company. Johnson &

Join for free to read a longer excerpt or purchase this article

Interview with the CEO, President and Director: Aldeyra Therapeutics Inc. (NASDAQ:ALDX)

Top Company Interviews

CEO INTERVIEWS

SECTOR ROUNDTABLES

MONEY MANAGER INTERVIEWS

ANALYST INTERVIEWS

Interview with the CEO, President and Director: Aldeyra Therapeutics Inc. (NASDAQ:ALDX)

Top Company Interviews

Register for a Free Account to gain greater access to The Wall Street Transcript right now

CEO INTERVIEWS

SECTOR ROUNDTABLES

MONEY MANAGER INTERVIEWS

ANALYST INTERVIEWS